Cargando…

Construction and Preclinical Evaluation of (211)At Labeled Anti-mesothelin Antibodies as Potential Targeted Alpha Therapy Drugs

Targeted alpha therapy (TAT) is a promising tumor therapy that can specifically transport α particle to the vicinity of tumor cells while the normal cells are only slightly irradiated. Mesothelin is a highly promising molecular signature for many types of solid tumors including malignant mesotheliom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xudong, Ma, Wenzong, Liu, Weihao, Ma, Huan, Yang, Yuanyou, Wang, Yugang, Liu, Ning, Yang, Gen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Regular Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482154/ https://www.ncbi.nlm.nih.gov/pubmed/32648573 http://dx.doi.org/10.1093/jrr/rraa049

Ejemplares similares

Preclinical Development of [(211)At]meta- astatobenzylguanidine ([(211)At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
por: Batra, Vandana, et al.
Publicado: (2022)

Targeted alpha therapy using astatine ((211)At)-labeled phenylalanine: A preclinical study in glioma bearing mice
por: Watabe, Tadashi, et al.
Publicado: (2020)

Intratumoral administration of astatine-211-labeled gold nanoparticle for alpha therapy
por: Kato, Hiroki, et al.
Publicado: (2021)

Cancer stem‐like cells with hybrid epithelial/mesenchymal phenotype leading the collective invasion
por: Quan, Qianghua, et al.
Publicado: (2020)

Effective Treatment of SSTR2-Positive Small Cell Lung Cancer Using (211)At-Containing Targeted α-Particle Therapy Agent Which Promotes Endogenous Antitumor Immune Response
por: Qin, Shanshan, et al.
Publicado: (2023)

Astatine-211-Labeled Gold Nanoparticles for Targeted Alpha-Particle Therapy via Intravenous Injection
por: Huang, Xuhao, et al.
Publicado: (2022)

Gold Nanostars: A Novel Platform for Developing (211)At-Labeled Agents for Targeted Alpha-Particle Therapy
por: Liu, Yang, et al.
Publicado: (2021)

Preclinical Evaluation of Radiation-Induced Toxicity in Targeted Alpha Therapy Using [(211)At] NaAt in Mice: A Revisit()
por: Liu, Yuwei, et al.
Publicado: (2020)

Human dosimetry of free (211)At and meta-[(211)At]astatobenzylguanidine ((211)At-MABG) estimated using preclinical biodistribution from normal mice
por: Ukon, Naoyuki, et al.
Publicado: (2020)

Stabilization of an (211)At-Labeled Antibody with Sodium Ascorbate
por: Manabe, Shino, et al.
Publicado: (2021)

Bisecting-GlcNAc on Asn388 is characteristic to ERC/mesothelin expressed on epithelioid mesothelioma cells
por: Fujihira, Haruhiko, et al.
Publicado: (2021)

Cytotoxicity of alpha-particle-emitting astatine-211-labelled antibody in tumour spheroids: no effect of hyperthermia.
por: Hauck, M. L., et al.
Publicado: (1998)

Targeted α-therapy using astatine ((211)At)-labeled PSMA1, 5, and 6: a preclinical evaluation as a novel compound
por: Watabe, Tadashi, et al.
Publicado: (2022)

Mesothelin-Specific Immune Responses and Targeted Immunotherapy for Mesothelin-Expressing Tumors
por: Einama, Takahiro, et al.
Publicado: (2017)

Alpha radionuclide-chelated radioimmunotherapy promoters enable local radiotherapy/chemodynamic therapy to discourage cancer progression
por: Zhang, Jiajia, et al.
Publicado: (2022)

Intratumour injection of immunoglobulins labelled with the alpha-particle emitter 211At: analyses of tumour retention, microdistribution and growth delay.
por: Larsen, R. H., et al.
Publicado: (1998)

Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin
por: Liu, Xiufen, et al.
Publicado: (2022)

Preclinical assessment of a novel human antibody VH domain targeting mesothelin as an antibody-drug conjugate
por: Sun, Zehua, et al.
Publicado: (2023)

Targeting mesothelin in ovarian cancer
por: Ghafoor, Azam, et al.
Publicado: (2018)

A Functional EXXEK Motif is Essential for Proton Coupling and Active Glucosinolate Transport by NPF2.11
por: Jørgensen, Morten Egevang, et al.
Publicado: (2015)

Radioimmunotherapy with an (211)At‐labeled anti–tissue factor antibody protected by sodium ascorbate
por: Takashima, Hiroki, et al.
Publicado: (2021)

Liver myofibroblasts of murine origins express mesothelin: Identification of novel rat mesothelin splice variants*
por: Fausther, Michel, et al.
Publicado: (2017)

Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors in vivo
por: Ye, Lin, et al.
Publicado: (2019)

An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin
por: Snell, Daniel, et al.
Publicado: (2023)

Challenges of Anti-Mesothelin CAR-T-Cell Therapy
por: Zhai, Xuejia, et al.
Publicado: (2023)

Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)
por: Le, Kai, et al.
Publicado: (2020)

The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice
por: Zhang, Qian, et al.
Publicado: (2021)

Demonstration of highly specific toxicity of the α-emitting radioimmunoconjugate(211)At-rituximab against non-Hodgkin's lymphoma cells
por: Aurlien, E, et al.
Publicado: (2000)

The hen model of human ovarian cancer develops anti-mesothelin autoantibodies in response to mesothelin expressing tumors
por: Yu, Yi, et al.
Publicado: (2011)

Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment
por: Zhang, Xianyu, et al.
Publicado: (2022)

Tumor Targeting of (211)At-Labeled Antibody under Sodium Ascorbate Protection against Radiolysis
por: Takashima, Hiroki, et al.
Publicado: (2022)

Eradicating mesothelin-positive human gastric and pancreatic tumors in xenograft models with optimized anti-mesothelin antibody–drug conjugates from synthetic antibody libraries
por: Hsu, Hung-Ju, et al.
Publicado: (2021)

Folate Receptor Alpha, Mesothelin and Megakaryocyte Potentiating Factor as Potential Serum Markers of Chronic Kidney Disease
por: Somers, Elizabeth B, et al.
Publicado: (2014)

Modulating Mesothelin Shedding to Improve Therapy
por: Zhang, Yujian, et al.
Publicado: (2012)

Mesothelin as a biomarker for targeted therapy
por: Lv, Jiang, et al.
Publicado: (2019)

Histoepigenetic analysis of the mesothelin network within pancreatic ductal adenocarcinoma cells reveals regulation of retinoic acid receptor gamma and AKT by mesothelin
por: Lurie, Eugene, et al.
Publicado: (2020)

Multiple proteases are involved in mesothelin shedding by cancer cells
por: Liu, Xiufen, et al.
Publicado: (2020)

Manual on the proper use of meta-[(211)At] astato-benzylguanidine ([(211)At] MABG) injections in clinical trials for targeted alpha therapy (1st edition)
por: Ukon, Naoyuki, et al.
Publicado: (2022)

Plasma Mesothelin as a Novel Diagnostic and Prognostic Biomarker in Colorectal Cancer
por: Li, Shuwei, et al.
Publicado: (2017)

Targeted-Alpha-Therapy Combining Astatine-211 and anti-CD138 Antibody in a Preclinical Syngeneic Mouse Model of Multiple Myeloma Minimal Residual Disease
por: Gouard, Sébastien, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_siuoqshaq5v88mfle0snbfdf91